

Generic Drug Development and Globally Divergent Regulations

SBIA Generic Drug Annual Forum; April 26-27 2022

Sarah Ibrahim, Ph.D.

Associate Director of Global Generic Drug Affairs

Office of Generic Drugs

Center for Drug Evaluation and Research

U.S. Food and Drug Administration

Agenda







Generic Drug Cluster and Parallel Scientific Advice




Paving the Path to Harmonization



GENERIC DRUGS AND PATIENT COSTS

ANNUAL SAVINGS FROM GENERICS AND BIOSIMILARS (\$BILLIONS)




- The average generic copay: \$6.61
- The average brand-name copay:
 \$55.82
- 93% of generics have a copay less than \$20, while only 51% of brands have a copay less than \$20




Generic Drug Global Landscape


Global generic drugs market snapshot



Generic Drugs Market-Market Size, Trends Analysis, Segment Forecasts, Regional Position 2021-2027

GLOBAL PHARMACEUTICAL INDUSTRY





Distribution of the FY2020 Site Catalog by Application Type https://www.fda.gov/news-events/congressional-testimony/covid-19-and-beyond-oversight-fdas-foreigndrug-manufacturing-inspection-process-06022020 https://www.fda.gov/media/151561/download

FDA



MANUFACTURING SITE DEMOGRAPHICS

Country	Sites in FY2020	Sites maintained	Sites Removed	Sites Added	Percentage Shift				40,000 ┏							
					% Removed	% Added	% Net	ted	ted							
UNITED STATES	1780	1644	286	136	-16.1%	7.6%	-8.4%	tes Lis	35,000 -							
All Others	1266	1152	170	114	-13.4%	9.0%	-4.4%		30,000							
INDIA	502	457	53	45	-10.6%	9.0%	-1.6%	Number	15,000							
CHINA	367	334	70	33	-19.1%	9.0%	-10.1%		10,000							
GERMANY	160	150	26	10	-16.3%	6.3%	-10.0%		5,000							
CANADA	146	137	19	9	-13.0%	6.2%	-6.8%									
TOTAL	4221	3874	624	347	-14.8%	8.2%	-6.6%		0		AND	A		NDA		BLA
													Ap	oplication	Туре	
										U	.S.	EU			Canada	Latin America
										In	dia	Res	t of World		China	

https://www.fda.gov/media/151561/download

GENERIC DRUG GLOBAL AFFAIRS PROGRAM


•Ensuring a strong FDA impact by promoting a high level of quality culture and standards


 Information Collection and Dissemination to assist in making better regulatory decisions about the pharmaceutical products that are being developed and exported for the U.S. market

 Identify emerging regulatory changes and manage proactive engagement with stakeholders concerning issues related to the pharmaceutical regulations

•Engage proactively and consistently with regulatory counterparts and industry representatives to facilitate FDA's domestic mission of assuring the safety, efficacy, and quality of FDA-regulated products

ADVANCES AND CHALLENGES FOR CURRENT REGULATORY FRAMFWORKS





Source: Industrial Journals, Experts Interview, Technical Publications, and Precedence Research Analysis, 2021

approach for regulatory standards related to the development and approval of complex generic products.

Global generic drugs market, by route of administration, 2020 & 2027 (%)

Stern S, Coghlan J, Krishnan V, et al. Research and Education Needs for Complex Generics. Pharmaceutical Research. 2021 Dec;38(12):1991-2001. DOI: 10.1007/s11095-021-03149-y. PMID: 34950975; PMCID: PMC8732887.

FDA

GAPS FOR COMPLEX GENERIC DRUG APPROVAL

There are a significant number of important complex products that are off patent but lack generic competition.

It is estimated that the United States experiences an annual lost savings of \$1.3 billion from seven complex generics that are currently approved in Europe and/or Canada but not the United States.

DRUG NAME (GENERIC NAME)	MANUFACTURER	CONDITIONS TREATED	FIRST APPROVED C = CANADA, EU = EUROPE	US SALES (2019, \$ MILLION)	
Abraxane* (paclitaxel)	Bristol Myers Squibb	Breast, lung, and pancreatic cancers	Mar. 2019 (EU)	\$122	
Forteo* (teriparatide)	Eli Lilly	Osteoporosis	Aug. 2019 (C) Oct. 2016 (EU)	\$646	
Invega Sustenna* (paliperidone)	Janssen/Johnson & Johnson	Schizophrenia, schizoaffective disorder	May 2019 (C) Jul. 2019 (EU)	\$1,685*	
Restasis* (cyclosporine)	Allergan/AbbVie	Suppressed tear production	Mar. 2017 (C)	\$1,138	
Risperdal Consta [®] (risperidone)	Janssen/Johnson & Johnson	Schizophrenia, bipolar I disorder	Oct. 2020 (EU)	\$314	
andostatin LAR* Novartis octreotide)		Symptoms of certain metastatic carcinoid tumors	Aug. 2020 (C) Apr. 2019 (EU)	\$881	
Venofer* American Regent/ (iron sucrose) Daiichi Sankyo		Iron deficiency caused by chronic kidney disease	Jun. 2018 (EU)	\$299	

9

FD/

COMPLEX **GENERICS AND GLOBAL MARKET** ACCESS



FD/

exchange of information enabling accelerated product development


> **Research** and investment

ICH AND OGD

- Global harmonization for generic drugs dates back to 2001 WHO report
- FDA strategically leveraged ICH reform initiated at the end of 2015 to propose generic drug initiatives
- Established a unique global affair program at OGD at the end of 2015
- Advocating for the expansion of the ICH portfolio to include generic drug standards
- Proposed a generic drug topic to ICH for guidance development to industry on specific generic drug topics

KEY PROPOSALS IN THE ICH REFLECTION PAPER

Develop a series of ICH guidelines on standards for demonstrating equivalence [e.g., bioequivalence (BE)] for



(2) more complex dosage forms and products

Additional Strength Waiver for Immediate Release

Statistical Analysis for BE

BE Analysis for Highly Variable Drugs

BE Analysis for Narrow Therapeutic Index

BE for Modified Release oral dosage forms

BE for Complex Products

- Inhalation
- Topical Dermatological
- Long-acting Injectable
- Other (e.g., Ophthalmic, Otic, Vaginal)

Model-based BE

M13 Guideline (Series), Annex, or Addendum

Potential New Guideline

New Guideline

FD/



PROSPECTIVE HARMONIZATION EFFORTS









CONSENSUS BUILDING - TECHNICAL DOCUMENT

CONSENSUS ON TECHNICAL DOCUMENT / B. DRAFT GUIDELINE ADOPTION BY REGULATORS



REGULATORY CONSULTATION AND DISCUSSION



ADOPTION OF AN ICH HARMONISED GUIDELINE



IMPLEMENTATION

This Photo by Unknown Author is licensed under <u>CC BY-SA-NC</u> WWW.FDA.GOV



FIRST GENERIC DRUG CLUSTER

Discussion of regulatory approaches to Generic Drug development

- Achieve a common understanding of each Agency's regulatory requirements for approval and current thinking on topics related to generic drug development through information sharing on approval requirements and recommendations conveyed in guidance documents.
- Offer a confidential forum for exchange and discussion on policies in development, including draft guidances for industry, and the scientific basis for decisions on those policies.
- Provide a forum for a discussion of general and product/class-related scientific review issues and foster alignment in approaches to scientific evaluation whenever possible.
- Address long term safety issues and ensure a global safety net for generic drugs through confidential sharing of reports.



https://www.fda.gov/drugs/genericdrugs/global-generic-drug-affairs

GLOBAL DIALOGUE **BRIDGES THE GAPS FOR** COMPLEX **GENERIC DRUG** APPROVAL

- Identify key differences among regulatory agencies regarding the approval of complex generics
- Identify aspects hindering fast approval of complex generics
- •Case studies and experiences with complex generics
- Reach consensus regarding approval standards when possible



FDA/EMA Bilateral

- The pilot established a new PSA process for complex generic drugs (FDA)/hybrid products (EMA-European Medicines Agency)
- A new addition to the existing PSA programs for new drugs (OND) and vaccines or gene therapies (CBER)

Launched September 15, 2021

PSA principles document can be accessed via the Office of Generic Drugs Global Affairs website

https://www.fda.gov/drugs/generic-drugs/global-genericdrug-affairs

PARALLEL SCIENTIFIC ADVICE (PSA) PILOT



OVERALL GOALS OF PSA PILOT

To provide a mechanism for EMA and FDA assessors to concurrently exchange with applicants their views on scientific issues during the development of **complex generic drug/hybrid products**

- increase dialogue between the two agencies and applicants from the beginning of the lifecycle of a complex generic drug product
- provide a deeper understanding of the basis of regulatory decisions
- optimize product development
- avoid unnecessary replication of studies or unnecessary diverse testing methodologies

The agencies conduct PSA meetings under the auspices of the confidentiality arrangement between the European Commission, the EMA, and FDA

Voluntary

Meeting requests will be received until enough PSA meetings are held to support the pilot program


 Candidates for the PSA program include product development programs that may benefit from the PSA process by potential harmonized approaches

"For example, the applicant may use the PSA program to determine whether a study design(s) might be acceptable to both regulatory agencies. Studies that may benefit from the PSA process include comparative non-clinical and comparative clinical studies involving innovative bioequivalence study designs and the use of methodologies such as modelling and simulation."

PSA HIGHLIGHTS



Proposed EMA-FDA PSA Pilot for Complex Generic Drug Products Timeline



PSA PROCESSES

The PSA process is designed to align the process and timeline of the pre-ANDA meeting at the FDA as much as possible with the process and timeline mandated by EMA <u>Scientific Advice Working Party</u> (SAWP) for their Scientific Advice (SA) process

Stage 1: PSA Meeting Requests (14 days)

 Submit one single "Request for PSA" letter (justification letter) to both

emainternational@ema.europa.eu preANDAHelp@fda.hhs.gov

No full package needed

Stage 2: Meeting Preparation and Conduct (~120 days)

- Day 1: Once the meeting is granted, full package will be submitted
- ~Day 120: trilateral meeting between applicant, EMA and FDA

Stage 3: Post-Meeting Agency Communication (30 days)

19

REGULATORY HARMONIZATION AND CHALLENGES

Social, economic, cultural, legal, and political differences

Risk tolerance, regulatory policies, and decision-making processes differences

Nomenclature, terminology, and labeling

Attributes for assessment of therapeutic equivalence





QUESTIONS?